Sign In
Buy VBIO
$0.83
+0 (+0%)
At Close: Jun 03, 2026
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
04:38pm, Tuesday, 19'th May 2026
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage inna
Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript
06:10pm, Thursday, 14'th May 2026
Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
04:31pm, Thursday, 14'th May 2026
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics SAN ANTONIO, May 14,
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
04:05pm, Thursday, 14'th May 2026
First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity Bioworks Conference Call to be Hel
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
08:01am, Monday, 11'th May 2026
SAN ANTONIO, Texas, May 11, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute R
Senator John Cornyn recognizes facility's role in advancing radiation countermeasures for cancer patients and U.S. warfighters; Mayor Gina Ortiz Jones, Office of Senator Cornyn, and Velocity Bioworks
Initial Study to Evaluate Entolimod™ for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome — an Indication for Which No Currently Approved or Stockpiled Countermeasure
Valion Bio Appoints Melinda Lackey as General Counsel
04:05pm, Monday, 04'th May 2026
/PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod for
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
08:01am, Tuesday, 28'th Apr 2026
Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswire/ -- V
Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility
11:45pm, Thursday, 02'nd Sep 2021
CLEVELAND, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC Mkts: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the
